Skip to main content
. 2022 Nov 17;13:1003651. doi: 10.3389/fimmu.2022.1003651

Figure 3.

Figure 3

Mechanistic model of the action of monoclonal antibodies against immune molecules in GBM therapy. Classical immune checkpoints such as CTLA-4, PD-1, B7-H6, B7-H4, and TIM-3 bind to their ligands to inhibit T-cell activation and proliferation, thereby creating an immunosuppressive microenvironment. Blocking these immune checkpoint molecules by single or combination therapy with monoclonal antibodies may serve as a potential treatment for glioblastoma.